Searching “how much does Wegovy cost” usually turns up half a dozen different numbers, and they all look official. You are not imagining it: what Wegovy costs depends on who is paying. Here is the clear breakdown, with every figure tied to a named source, because GLP-1 pricing has changed more than once in the past year and any article without dates is already out of step.
Every figure below is as of 2026. Wegovy is Novo Nordisk’s brand-name semaglutide, FDA-approved for chronic weight management; it is the weight-management approval, not the diabetes one. Start with the highest number, the one almost nobody actually pays.
Wegovy’s list price
Wegovy’s list price is about $1,349 a month for a four-week supply, according to Managed Healthcare Executive. That is the manufacturer’s set price before any discount, insurance, or savings program.
Here is the part that matters: the list price is close to fiction for the average patient. It is the starting point for negotiations among the manufacturer, insurers, and pharmacy benefit managers, not what most people hand over at the counter. We include it because it is the number a pharmacy rings up when Wegovy is processed with no program and no coverage applied, and because it sets the baseline for understanding how much every other route cuts off.
Wegovy comes as a single-dose pen for once-weekly use, in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths. The dose you start on is not the maintenance dose: a typical plan titrates up over several weeks, and that matters for your budget, because some price offers apply only to the starting doses.
The cash price without insurance
If you are not using insurance, you are not stuck with the list price. As of 2026 there are three published self-pay routes for brand-name Wegovy:
| Where you buy | Price without insurance (4-week supply) | Source |
|---|
| Retail pharmacy, no program | near list price, ~$1,349 | Managed Healthcare Executive |
| NovoCare Pharmacy (direct delivery) | $499 per month, all doses | Managed Healthcare Executive |
| NovoCare self-pay offer | introductory price for first 2 fills, then $349/mo (0.25–2.4 mg) or $399/mo (HD 7.2 mg) | Wegovy cost & coverage |
| GoodRx (Novo Nordisk cash price) | $199 intro, 2 fills; then $349/mo | GoodRx |
Two details are worth pinning down. First, the introductory offer on the first two fills is listed as running through June 30, 2026, so check whether it still applies when you fill, and budget for the maintenance price rather than the promotional one. Second, NovoCare ships Wegovy to your door, but the same Novo Nordisk cash price is also available at major chains and through GoodRx, so you are not locked into a single channel.
There is also now a Wegovy pill (oral semaglutide), the first pill version FDA-approved for weight loss. It carries its own pricing, starting around $149 a month on the lowest doses for a limited time and climbing on the higher maintenance doses. If the pill interests you more than the injection, ask your clinician which dose you would be on and what the price settles at after the introductory window.
Why does the cash number swing so much across those rows? Because each program covers different doses and time windows. The price you actually pay is a function of your fill, your dose, and whichever offer is live that month. Treat the table as a map; the pharmacy counter gives you the quote.
Why insurance changes everything (and why it sometimes won’t pay)
For a lot of people the real question is not “what’s the cash price?” but “will my plan cover it?” There, the answer turns on your coverage and your diagnosis.
Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and since March 2024 also to reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease and obesity or overweight, per the FDA. That cardiovascular indication matters for coverage: a plan that won’t pay for a “weight-loss” drug sometimes will when a cardiovascular indication is involved.
Even so, many commercial plans exclude weight-management drugs entirely, and the plans that do cover them often require prior authorization, meaning your clinician has to document that you meet the criteria before the insurer pays. When there is coverage, Novo Nordisk says about 90% of patients on a plan that covers Wegovy pay $0 to $25 a month with the savings card, per Managed Healthcare Executive. That card requires active commercial insurance and excludes anyone on Medicare or Medicaid.
Medicare is its own case. Part D has not covered drugs prescribed for weight loss alone, but a federal demonstration, the Medicare GLP-1 Bridge, will give eligible Part D enrollees access to GLP-1 medications approved for weight reduction, including Wegovy, at a $50 monthly copay starting July 1, 2026. Medicaid coverage, meanwhile, varies state by state, per KFF’s research.
The pattern mirrors Ozempic: the price you actually pay is a function of your prescription’s indication, your plan’s formulary, and your eligibility for manufacturer programs. For the parallel case with numbers, see how much Ozempic costs in the US. Confirm all three before you assume any figure, including the ones in this article.
Wegovy versus the transparent cash-pay route
For many people the insurance maze ends in a denial letter, and the realistic comparison becomes one cash price against another. That is the comparison worth making carefully.
One route is brand-name Wegovy at its self-pay price, with the prescription coming from your own doctor or a telehealth visit. The other route is cash-pay telehealth programs, which offer a different model rather than a discount on the same product. REMEVi sits in that second group, and the value is the care around the prescription: a physician-led team reviews your health history and eligibility before anything is prescribed, REMEVi’s transparent pricing means the number you see up front is the number you pay with no insurance call and no prior-authorization wait, medications ship from NPI-verified US pharmacies, and a care coordinator checks in through the early titration weeks when questions actually come up. If you want the pharmacology first, start with semaglutide, explained, and to see how the model compares, compare REMEVi against other options.
Some telehealth programs, REMEVi included, work with compounded semaglutide when a licensed provider determines it is appropriate for the individual patient. It is worth being exact about what that means. Compounded semaglutide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. A licensed clinician should walk you through that distinction before you choose either route.
The bottom line
As of 2026, Wegovy’s list price is about $1,349 a month, but almost no one pays it. Without insurance, Novo Nordisk’s self-pay routes put the brand injection between $199 and $499 a month depending on the fill and the offer, with an introductory price on the first two fills listed through June 30, 2026. With a plan that covers Wegovy, most patients pay $0 to $25 a month. The right move is to confirm your indication, your plan’s answer, and your long-term maintenance-dose cost before you commit to any route.
If you would rather have a clinician walk you through it than decode formularies alone, that is what we are here for. Your Health. Your Terms. Real doctors. Real care. remevihealth.com
This article is for general information and does not constitute medical advice. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded semaglutide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Prices cited are as of 2026, come from the named sources, and are subject to change without notice. Consult a licensed provider before starting any prescription treatment.
